Down-regulation of C12orf59 is associated with a poor prognosis and VHL mutations in renal cell carcinoma.
Down-regulation of C12orf59 is associated with a poor prognosis and VHL mutations in renal cell carcinoma.
复制标题
C12orf59 的下调与肾细胞癌的不良预后和 VHL 突变相关。
DOI：
10.18632/oncotarget.6829
复制
发表时间：
2016-02-09
期刊：
影响因子：
--
通讯作者：
Li Z
中科院分区：
文献类型：
--
作者：
Xie J;Zhu C;Wu J;Li C;Luo L;Xia L;Li X;Gui Y;Cai Z;Li Z
C12orf59 是肾脏中新发现的基因。然而，C12orf59 表达与临床特征的关系尚不清楚。在此，我们的研究表明，C12orf59 在正常人体组织中广泛表达，在肾脏中表达水平较高，而其表达在一组癌细胞系中无法检测到。与相应的癌旁组织相比，RCC 中 C12orf59 的表达显着降低（P < 0.01）。 C12orf59表达降低与淋巴结状态（P < 0.05）、远处转移（P < 0.05）、生存率低（P < 0.001）（HR 3.00；95% CI，1.29-7.53）、VHL无义突变或移码突变（P < 0.01）以及UMPP基因无义突变或移码突变（P = 0.01）。因此，我们认为 C12orf59 表达状态的降低是 ccRCC 的预后生物标志物，并与 VHL 的丧失共同作用，同时促进肾癌发生。
C12orf59 is newly identified gene in kidney. However, the relation of C12orf59 expression and clinic features is unknown. Here, our study showed that C12orf59 was broadly expressed in normal human tissues with high expression levels in kidney while its expression is beyond detectable in a panel of cancer cell lines. C12orf59 expression in RCC was significantly decreased compared with corresponding adjacent noncancerous tissues (P < 0.01). The decreased C12orf59 expression was correlated with lymph node status (P < 0.05), distant metastases (P < 0.05), poor survival (P < 0.001) (HR 3.00; 95% CI, 1.29–7.53), VHL non-sense mutations or frame-shift mutations (P < 0.01), and UMPP gene non-sense mutations or frame-shift mutations (P = 0.01). Thus, we propose that the decreased C12orf59 expression status is a prognostic biomarker of ccRCC and cooperates with the loss of VHL all the while promoting renal carcinogenesis.